{"transactions":[{"id":721305,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter."}],"balance_after":205804,"derivative":{"exercise_price":1.03,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721304,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":6337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter."}],"balance_after":230804,"derivative":{"exercise_price":1.03,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":6337},"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721303,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":18663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares."}],"balance_after":9,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":18663},"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721302,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":34.8437,"value":66203.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1047205,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721301,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":23100,"price":34.2633,"value":791482.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1049105,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721300,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":1.03,"value":25750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1072205,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721299,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":11579,"price":35.9119,"value":415823.8901,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1047205,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721298,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":13421,"price":35.1336,"value":471528.0456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1058784,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721297,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":6337,"price":1.03,"value":6527.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1072205,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":721296,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:11.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":18663,"price":0.67,"value":12504.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1065868,"source":{"system":"sec-edgar","filing":"0001193125-26-292526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526292526/ownership.xml","form_type":"4"}},{"id":814480,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-04-06T21:48:48.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":30078,"price":24.58,"value":739317.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. (\"BEAM\") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 616 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026."}],"balance_after":1047205,"source":{"system":"sec-edgar","filing":"0001193125-26-144086","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526144086/ownership.xml","form_type":"4"}},{"id":822924,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares."}],"balance_after":18672,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":822923,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-30","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares."}],"balance_after":43672,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":822922,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-31","kind":"grant","planned":true,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date."}],"balance_after":1076667,"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":822921,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":22.7634,"value":569085.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.34 to $23.21, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":986667,"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":822920,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":0.67,"value":16750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1011667,"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":822919,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-30","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":22.3692,"value":559230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.03 to $22.70, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":986667,"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":822918,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-04-01T22:32:14.000Z","date":"2026-03-30","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":0.67,"value":16750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1011667,"source":{"system":"sec-edgar","filing":"0001193125-26-138348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526138348/ownership.xml","form_type":"4"}},{"id":925240,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-31","kind":"grant","planned":true,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date."}],"balance_after":180000,"derivative":{"exercise_price":27.62,"expiration_date":"2036-01-31","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925239,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-30","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares."}],"balance_after":68672,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925238,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-29","kind":"exercise","planned":true,"acquired":false,"shares":5664,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares."}],"balance_after":93672,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":5664},"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925237,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-29","kind":"exercise","planned":true,"acquired":false,"shares":19336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the \"Price Condition\"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022, and December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":19336},"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925236,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-30","kind":"sale","planned":true,"acquired":false,"shares":2906,"price":29,"value":84274.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":986667,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925235,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-30","kind":"sale","planned":true,"acquired":false,"shares":22094,"price":28.2734,"value":624672.4996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":989573,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925234,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-30","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":0.67,"value":16750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1011667,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925233,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-29","kind":"sale","planned":true,"acquired":false,"shares":8667,"price":29.7428,"value":257780.8476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":986667,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925232,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-29","kind":"sale","planned":true,"acquired":false,"shares":16333,"price":29.1925,"value":476801.1025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":995334,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925231,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-29","kind":"exercise","planned":true,"acquired":true,"shares":5664,"price":0.67,"value":3794.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1011667,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":925230,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-02T21:05:08.000Z","date":"2026-01-29","kind":"exercise","planned":true,"acquired":true,"shares":19336,"price":0.67,"value":12955.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1006003,"source":{"system":"sec-edgar","filing":"0001193125-26-033600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526033600/ownership.xml","form_type":"4"}},{"id":1024648,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T20:05:03.000Z","date":"2025-10-02","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the \"Price Condition\"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022."}],"balance_after":19336,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-230084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312525230084/ownership.xml","form_type":"4"}},{"id":1024647,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T20:05:03.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the \"Price Condition\"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022."}],"balance_after":44336,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-230084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312525230084/ownership.xml","form_type":"4"}},{"id":1024646,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-03T20:05:03.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":24.6267,"value":615667.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":986667,"source":{"system":"sec-edgar","filing":"0001193125-25-230084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312525230084/ownership.xml","form_type":"4"}},{"id":1024645,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-03T20:05:03.000Z","date":"2025-10-02","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":0.67,"value":16750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."}],"balance_after":1011667,"source":{"system":"sec-edgar","filing":"0001193125-25-230084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312525230084/ownership.xml","form_type":"4"}},{"id":1024644,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-03T20:05:03.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":24.5062,"value":612655.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":986667,"source":{"system":"sec-edgar","filing":"0001193125-25-230084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312525230084/ownership.xml","form_type":"4"}},{"id":1024643,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-03T20:05:03.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":0.67,"value":16750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. (\"BEAM\") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025."}],"balance_after":1011667,"source":{"system":"sec-edgar","filing":"0001193125-25-230084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312525230084/ownership.xml","form_type":"4"}},{"id":1179738,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-04T01:52:04.000Z","date":"2025-04-01","kind":"sale","planned":true,"acquired":false,"shares":30663,"price":18.3506,"value":562684.4478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. (\"BEAM\") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 753 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2025."}],"balance_after":986249,"source":{"system":"sec-edgar","filing":"0000950170-25-050857","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025050857/ownership.xml","form_type":"4"}},{"id":1183615,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-02T23:10:30.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person under the Beam Therapeutics Inc. (\"BEAM\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date."}],"balance_after":1016159,"source":{"system":"sec-edgar","filing":"0000950170-25-049759","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025049759/ownership.xml","form_type":"4"}},{"id":1183614,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T20:05:23.000Z","date":"2025-01-30","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 3, 2025, the Reporting Person filed a Form 4 (the \"Original Form 4\") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc."},{"field":"security","element":"securityTitle","label":"F2","text":"(Continued from footnote 1) (\"BEAM\"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM."},{"field":"kind","element":"transactionCoding","label":"F3","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the \"Price Condition\"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022."}],"balance_after":69336,"derivative":{"exercise_price":0.67,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-049297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025049297/ownership.xml","form_type":"4/A","original_submission_date":"2025-02-03"}},{"id":1183613,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-04-02T20:05:23.000Z","date":"2025-01-30","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":0.67,"value":20100.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 3, 2025, the Reporting Person filed a Form 4 (the \"Original Form 4\") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc."},{"field":"security","element":"securityTitle","label":"F2","text":"(Continued from footnote 1) (\"BEAM\"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM."},{"field":"kind","element":"transactionCoding","label":"F3","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the \"Price Condition\"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022."}],"balance_after":968659,"source":{"system":"sec-edgar","filing":"0000950170-25-049297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025049297/ownership.xml","form_type":"4/A","original_submission_date":"2025-02-03"}},{"id":1287494,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-03T21:05:04.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date."}],"balance_after":155000,"derivative":{"exercise_price":25.92,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0000950170-25-012304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025012304/ownership.xml","form_type":"4"}},{"id":1287493,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-03T21:05:04.000Z","date":"2025-01-30","kind":"sale","planned":true,"acquired":false,"shares":200,"price":27.28,"value":5456.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024."}],"balance_after":908659,"source":{"system":"sec-edgar","filing":"0000950170-25-012304","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025012304/ownership.xml","form_type":"4"}},{"id":1287492,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-03T21:05:04.000Z","date":"2025-01-30","kind":"sale","planned":true,"acquired":false,"shares":29800,"price":26.7459,"value":797027.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $26.26 to $27.21 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":908859,"source":{"system":"sec-edgar","filing":"0000950170-25-012304","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025012304/ownership.xml","form_type":"4"}},{"id":1394572,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-10-02T21:49:39.000Z","date":"2024-09-30","kind":"sale","planned":true,"acquired":false,"shares":60000,"price":24.6004,"value":1476024.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.26 to $25.24, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 316 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024."}],"balance_after":938659,"source":{"system":"sec-edgar","filing":"0000950170-24-111732","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024111732/ownership.xml","form_type":"4"}},{"id":1467253,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-06-28T20:15:04.000Z","date":"2024-06-27","kind":"sale","planned":true,"acquired":false,"shares":60000,"price":24.5026,"value":1470156.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.17 to $24.93, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":998343,"source":{"system":"sec-edgar","filing":"0000950170-24-079065","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024079065/ownership.xml","form_type":"4"}},{"id":1549850,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T23:36:56.000Z","date":"2024-04-03","kind":"grant","planned":true,"acquired":true,"shares":53965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 13, 2019, the Reporting Person was granted an option to purchase 53,965 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 53,965 shares."}],"balance_after":53965,"derivative":{"exercise_price":4.22,"exercise_date":"2024-04-03","expiration_date":"2029-02-13","underlying":"Common Stock","underlying_shares":53965},"source":{"system":"sec-edgar","filing":"0000950170-24-041432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024041432/ownership.xml","form_type":"4"}},{"id":1549849,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T23:36:56.000Z","date":"2024-04-03","kind":"grant","planned":true,"acquired":true,"shares":99336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 8, 2018, the Reporting Person was granted an option to purchase 99,336 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares."}],"balance_after":99336,"derivative":{"exercise_price":0.67,"exercise_date":"2024-04-03","expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":99336},"source":{"system":"sec-edgar","filing":"0000950170-24-041432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024041432/ownership.xml","form_type":"4"}},{"id":1549848,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-03T23:36:56.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":18102,"price":32.13,"value":581617.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. (\"BEAM\") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1058343,"source":{"system":"sec-edgar","filing":"0000950170-24-041432","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024041432/ownership.xml","form_type":"4"}},{"id":1556409,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-01T20:10:08.000Z","date":"2024-03-31","kind":"grant","planned":true,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2024."}],"balance_after":1076445,"source":{"system":"sec-edgar","filing":"0000950170-24-039319","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024039319/ownership.xml","form_type":"4"}},{"id":1556408,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-01T20:10:08.000Z","date":"2024-03-28","kind":"sale","planned":true,"acquired":false,"shares":60000,"price":33.8567,"value":2031402.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.374 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":998262,"source":{"system":"sec-edgar","filing":"0000950170-24-039319","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024039319/ownership.xml","form_type":"4"}},{"id":1661852,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:05:18.000Z","date":"2024-01-31","kind":"grant","planned":true,"acquired":true,"shares":155000,"price":24.4,"value":3782000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date."}],"balance_after":155000,"derivative":{"exercise_price":24.4,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0000950170-24-010477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024010477/ownership.xml","form_type":"4"}},{"id":1661851,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:18.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":60000,"price":25.33,"value":1519800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $24.93 to $25.92 inclusive.  The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023."}],"balance_after":1058262,"source":{"system":"sec-edgar","filing":"0000950170-24-010477","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024010477/ownership.xml","form_type":"4"}},{"id":1925226,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-04-06T00:30:20.000Z","date":"2023-04-04","kind":"sale","planned":true,"acquired":false,"shares":6493,"price":29.0935,"value":188904.0955,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.81 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1117979,"source":{"system":"sec-edgar","filing":"0000899243-23-010819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010819/doc4.xml","form_type":"4"}},{"id":1925225,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-04-06T00:30:20.000Z","date":"2023-04-03","kind":"sale","planned":true,"acquired":false,"shares":5161,"price":30.31,"value":156429.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023."}],"balance_after":1124472,"source":{"system":"sec-edgar","filing":"0000899243-23-010819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010819/doc4.xml","form_type":"4"}},{"id":1934036,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T23:48:43.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":false,"shares":13850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.\n.."}],"balance_after":196904,"derivative":{"exercise_price":7.22,"expiration_date":"2029-05-17","underlying":"Common Stock","underlying_shares":13850},"source":{"system":"sec-edgar","filing":"0000899243-23-010137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010137/doc4.xml","form_type":"4"}},{"id":1934035,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T23:48:43.000Z","date":"2023-01-31","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date."}],"balance_after":112500,"derivative":{"exercise_price":43.45,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0000899243-23-010137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010137/doc4.xml","form_type":"4"}},{"id":1934034,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-31T23:48:43.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":true,"shares":13850,"price":7.22,"value":99997.0,"ownership":{"direct":true},"balance_after":1129153,"source":{"system":"sec-edgar","filing":"0000899243-23-010137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010137/doc4.xml","form_type":"4"}},{"id":1934033,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-31T23:48:43.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person under BEAM's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date."}],"balance_after":1115303,"source":{"system":"sec-edgar","filing":"0000899243-23-010137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010137/doc4.xml","form_type":"4"}},{"id":1934032,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-31T23:48:43.000Z","date":"2023-03-06","kind":"other","planned":false,"acquired":true,"shares":225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of Beam Therapeutics Inc. (\"BEAM\") common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 308 shares and acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022."}],"balance_after":1059053,"source":{"system":"sec-edgar","filing":"0000899243-23-010137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924323010137/doc4.xml","form_type":"4"}},{"id":2127219,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":2188,"price":47.9143,"value":104836.4884,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.57 to $48.40, inclusive."}],"balance_after":103000,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127218,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":8235,"price":46.9143,"value":386339.2605,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.555, inclusive."}],"balance_after":105188,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127217,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":4569,"price":46.1882,"value":211033.8858,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive."}],"balance_after":113423,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127216,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":5008,"price":44.9268,"value":224993.4144,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive."}],"balance_after":117992,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127215,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":2909,"price":47.8944,"value":139324.8096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.68 to $48.17, inclusive."}],"balance_after":1058520,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127214,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":11756,"price":46.8813,"value":551136.5628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.52, inclusive."}],"balance_after":1061429,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127213,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":7768,"price":46.192,"value":358819.456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive."}],"balance_after":1073185,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2127212,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-02T20:30:23.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":7567,"price":44.9246,"value":339944.4482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive."}],"balance_after":1080953,"source":{"system":"sec-edgar","filing":"0000899243-22-034759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322034759/doc4.xml","form_type":"4"}},{"id":2200313,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":2247,"price":67.8163,"value":152383.2261,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.72 to $68.49, inclusive."}],"balance_after":123000,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200312,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":201,"price":66.6095,"value":13388.5095,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.50 to $66.61, inclusive."}],"balance_after":125247,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200311,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":10599,"price":65.9188,"value":698673.3612,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.46 to $66.45, inclusive."}],"balance_after":125448,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200310,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":6953,"price":64.8804,"value":451113.4212,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.38, inclusive."}],"balance_after":136047,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200309,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":173,"price":68.49,"value":11848.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1088520,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200308,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":2848,"price":67.7996,"value":193093.2608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.45 to $67.87, inclusive."}],"balance_after":1088693,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200307,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":1562,"price":66.7448,"value":104255.3776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.44 to $67.37, inclusive."}],"balance_after":1091541,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200306,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":15236,"price":65.8241,"value":1002895.9876,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.43 to $66.34, inclusive."}],"balance_after":1093103,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2200305,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-07-29T20:06:01.000Z","date":"2022-07-28","kind":"sale","acquired":false,"shares":10181,"price":64.8688,"value":660429.2528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.42, inclusive."}],"balance_after":1108339,"source":{"system":"sec-edgar","filing":"0000899243-22-027077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322027077/doc4.xml","form_type":"4"}},{"id":2234307,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T17:00:35.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":15500,"derivative":{"exercise_price":14.04,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-22-036366","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919122036366/doc4.xml","form_type":"4"}},{"id":2286558,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"exercise","acquired":false,"shares":47204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested."}],"balance_after":237141,"derivative":{"exercise_price":1.03,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":47204},"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286557,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"exercise","acquired":false,"shares":12246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested."}],"balance_after":210754,"derivative":{"exercise_price":7.22,"expiration_date":"2029-05-17","underlying":"Common Stock","underlying_shares":12246},"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286556,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":357,"price":40.88,"value":14594.16,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.70 to $40.96, inclusive."}],"balance_after":143000,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286555,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":2348,"price":39.73,"value":93286.04,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.51 to $40.32, inclusive."}],"balance_after":143357,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286554,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":3100,"price":38.75,"value":120125.0,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.405 to $39.261, inclusive."}],"balance_after":145705,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286553,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":7745,"price":37.84,"value":293070.8,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $37.38 to $38.37, inclusive."}],"balance_after":148805,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286552,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":6450,"price":36.98,"value":238521.0,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.36 to $37.34, inclusive."}],"balance_after":156550,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286551,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":1100,"price":40.73,"value":44803.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.08 to $40.80, inclusive."}],"balance_after":1118520,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286550,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":4503,"price":39.49,"value":177823.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.21 to $39.88, inclusive."}],"balance_after":1119620,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286549,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":6842,"price":38.32,"value":262185.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.09 to $38.67, inclusive."}],"balance_after":1124123,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286548,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":13655,"price":37.48,"value":511789.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $37.06 to $37.86, inclusive."}],"balance_after":1130965,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286547,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":3900,"price":36.59,"value":142701.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.36 to $36.97, inclusive."}],"balance_after":1144620,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286546,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"exercise","acquired":true,"shares":47204,"price":1.03,"value":48620.12,"ownership":{"direct":true},"balance_after":1148520,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2286545,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-05-02T22:51:00.000Z","date":"2022-04-28","kind":"exercise","acquired":true,"shares":12246,"price":7.22,"value":88416.12,"ownership":{"direct":true},"balance_after":1101316,"source":{"system":"sec-edgar","filing":"0000899243-22-016164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322016164/doc4.xml","form_type":"4"}},{"id":2308471,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-05T00:27:59.000Z","date":"2022-03-31","kind":"sale","acquired":false,"shares":6261,"price":59.11,"value":370087.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs."}],"balance_after":1089070,"source":{"system":"sec-edgar","filing":"0000899243-22-013487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322013487/doc4.xml","form_type":"4"}},{"id":2308470,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-05T00:27:59.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022."}],"balance_after":1095331,"source":{"system":"sec-edgar","filing":"0000899243-22-013487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322013487/doc4.xml","form_type":"4"}},{"id":2416846,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date."}],"balance_after":112500,"derivative":{"exercise_price":69.21,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416845,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested."}],"balance_after":284345,"derivative":{"exercise_price":1.03,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416844,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":2672,"price":68.16,"value":182123.52,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive."}],"balance_after":163000,"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416843,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":9408,"price":67.43,"value":634381.44,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive."}],"balance_after":165672,"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416842,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":4105,"price":66.48,"value":272900.4,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.00 to $66.94, inclusive."}],"balance_after":175080,"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416841,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":1900,"price":65.55,"value":124545.0,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive."}],"balance_after":179185,"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416840,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":1615,"price":64.46,"value":104102.9,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.17 to $64.50, inclusive."}],"balance_after":181085,"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}},{"id":2416839,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":34011,"kind":"person","name":"Evans John M.","position":1,"cik":"0001786304","reported_name":"Evans John M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:17.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":300,"price":63.45,"value":19035.0,"ownership":{"direct":false,"nature":"By John M. Evans, III 2018 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.26 to $63.58, inclusive."}],"balance_after":182700,"source":{"system":"sec-edgar","filing":"0000899243-22-004197","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322004197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-07"}}],"next_cursor":"2022-02-02T23:00:17.000000Z,2416839"}